SLC12A8对肿瘤发生与发展作用的研究进展
Research Advances on the Role of SLC12A8 in Tumorigenesis and Progression
DOI: 10.12677/acm.2025.1582390, PDF,   
作者: 唐辉阳, 韦玉喜, 张 超：赣南医科大学第一临床医学院，江西 赣州；余冬敏*：赣南医科大学第一附属医院乳腺诊疗中心，江西 赣州
关键词: SLC12A8；肿瘤；信号通路；乳腺癌；转运蛋白；SLC12A8； Cancer； Signaling Pathways； Breast Cancer； Transport Protein
摘要: SLC12A8是一种烟酰胺单核苷酸(Nicotinamide Mononucleotide, NMN)转运蛋白，属于溶质载体(Solute Carrier, SLC)家族成员，广泛参与多种生物学过程，包括代谢调节、炎症反应、细胞增殖与凋亡以及肿瘤的发生发展等。近年来，随着对肿瘤微环境和分子机制研究的深入，SLC12A8在肿瘤学领域的研究逐渐成为热点，越来越多的研究揭示其在肿瘤发生、进展以及转移中发挥重要作用。特别是在乳腺癌、膀胱癌、非小细胞肺癌及结直肠癌中，其表达水平与患者预后之间存在密切关联。本文旨在系统综述SLC12A8在肿瘤生物学中的研究进展，重点探讨其在乳腺癌、膀胱癌、非小细胞肺癌以及结直肠癌中的表达特征和作用机制，并结合现有研究成果，从分子信号转导、细胞功能调节和肿瘤微环境等方面分析其潜在的生物学意义。此外，本文还将展望未来关于SLC12A8靶向治疗的临床应用前景，以期为肿瘤精准医学提供新的思路。
Abstract: SLC12A8, a nicotinamide mononucleotide (NMN) transporter and member of the solute carrier (SLC) family, is widely involved in various biological processes, including metabolic regulation, inflammatory response, cell proliferation and apoptosis, as well as the occurrence and development of tumors. In recent years, with the deepening of research on the tumor microenvironment and molecular mechanisms, the study of SLC12A8 in the field of oncology has gradually become a hot topic, and more and more studies have revealed its important role in tumor occurrence, progression, and metastasis. Especially in breast cancer, bladder cancer, non-small cell lung cancer, and colorectal cancer, its expression level is closely associated with patient prognosis. This article aims to systematically review the research progress of SLC12A8 in tumor biology, focusing on its expression characteristics and mechanisms in breast cancer, bladder cancer, non-small cell lung cancer, and colorectal cancer, and analyzing its potential biological significance from the aspects of molecular signal transduction, cell function regulation, and tumor microenvironment based on existing research findings. Furthermore, this article will also look forward to the future clinical application prospects of SLC12A8 in targeted therapy, in order to provide new ideas for precision medicine in tumors.
文章引用：唐辉阳, 韦玉喜, 张超, 余冬敏. SLC12A8对肿瘤发生与发展作用的研究进展[J]. 临床医学进展, 2025, 15(8): 1496-1506. https://doi.org/10.12677/acm.2025.1582390

参考文献

[1] Gagnon, K.B. and Delpire, E. (2013) Physiology of SLC12 Transporters: Lessons from Inherited Human Genetic Mutations and Genetically Engineered Mouse Knockouts. American Journal of Physiology-Cell Physiology, 304, C693-C714. [Google Scholar] [CrossRef] [PubMed]
[2] Daigle, N.D., Carpentier, G.A., Frenette‐Cotton, R., Simard, M.G., Lefoll, M., Noël, M., et al. (2009) Molecular Characterization of a Human Cation‐Cl− Cotransporter (SLC12A8A, CCC9A) That Promotes Polyamine and Amino Acid Transport. Journal of Cellular Physiology, 220, 680-689. [Google Scholar] [CrossRef] [PubMed]
[3] Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z. and Zhao, J. (2014) Breast Cancer: Epidemiology and Etiology. Cell Biochemistry and Biophysics, 72, 333-338. [Google Scholar] [CrossRef] [PubMed]
[4] Grozio, A., Mills, K.F., Yoshino, J., Bruzzone, S., Sociali, G., Tokizane, K., et al. (2019) Author Correction: Slc12a8 Is a Nicotinamide Mononucleotide Transporter. Nature Metabolism, 1, 743-743. [Google Scholar] [CrossRef] [PubMed]
[5] Covarrubias, A.J., Perrone, R., Grozio, A. and Verdin, E. (2020) NAD+ Metabolism and Its Roles in Cellular Processes during Ageing. Nature Reviews Molecular Cell Biology, 22, 119-141. [Google Scholar] [CrossRef] [PubMed]
[6] Ito, N., Takatsu, A., Ito, H., Koike, Y., Yoshioka, K., Kamei, Y., et al. (2022) Slc12a8 in the Lateral Hypothalamus Maintains Energy Metabolism and Skeletal Muscle Functions during Aging. Cell Reports, 40, Article ID: 111131. [Google Scholar] [CrossRef] [PubMed]
[7] Gradishar, W.J., Moran, M.S., Abraham, J., et al. (2021) NCCN Guidelines ® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network, 19, 484-493.
[8] du Rusquec, P., Blonz, C., Frenel, J.S. and Campone, M. (2020) Targeting the PI3K/Akt/mTOR Pathway in Estrogen-Receptor Positive HER2 Negative Advanced Breast Cancer. Therapeutic Advances in Medical Oncology, 12, 1-12. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, J., Choi, J., Park, J., Park, C., Lee, S.M., Park, S.E., et al. (2018) Associations between Genetic Polymorphisms of Membrane Transporter Genes and Prognosis after Chemotherapy: Meta-Analysis and Finding from Seoul Breast Cancer Study (SEBCS). The Pharmacogenomics Journal, 18, 633-645. [Google Scholar] [CrossRef] [PubMed]
[10] Stearns, V., Davidson, N.E. and Flockhart, D.A. (2004) Pharmacogenetics in the Treatment of Breast Cancer. The Pharmacogenomics Journal, 4, 143-153. [Google Scholar] [CrossRef] [PubMed]
[11] Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., et al. (2005) Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. New England Journal of Medicine, 353, 1784-1792. [Google Scholar] [CrossRef] [PubMed]
[12] Medzhitov, R., Preston-Hurlburt, P. and Janeway, C.A. (1997) A Human Homologue of the Drosophila Toll Protein Signals Activation of Adaptive Immunity. Nature, 388, 394-397. [Google Scholar] [CrossRef] [PubMed]
[13] Takeda, K. and Akira, S. (2004) TLR Signaling Pathways. Seminars in Immunology, 16, 3-9. [Google Scholar] [CrossRef] [PubMed]
[14] Doyle, S.L. and O’Neill, L.A.J. (2006) Toll-Like Receptors: From the Discovery of NFκB to New Insights into Transcriptional Regulations in Innate Immunity. Biochemical Pharmacology, 72, 1102-1113. [Google Scholar] [CrossRef] [PubMed]
[15] Grivennikov, S.I., Greten, F.R. and Karin, M. (2010) Immunity, Inflammation, and Cancer. Cell, 140, 883-899. [Google Scholar] [CrossRef] [PubMed]
[16] Philip, M., Rowley, D.A. and Schreiber, H. (2004) Inflammation as a Tumor Promoter in Cancer Induction. Seminars in Cancer Biology, 14, 433-439. [Google Scholar] [CrossRef] [PubMed]
[17] Duan, T., Du, Y., Xing, C., Wang, H.Y. and Wang, R. (2022) Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Frontiers in Immunology, 13, Article 812774. [Google Scholar] [CrossRef] [PubMed]
[18] Li, L., Xia, J., Cui, R. and Kong, B. (2020) Solute Carrier Family 12 Member 8 Impacts the Biological Behaviors of Breast Carcinoma Cells by Activating TLR/NLR Signaling Pathway. Cytotechnology, 73, 23-34. [Google Scholar] [CrossRef] [PubMed]
[19] 李琪, 徐银莹, 谢冰雪, 等. 基于数据库挖掘分析SLC12A8在乳腺癌组织中的表达及与细胞耐药的关系[J]. 现代肿瘤医学, 2021, 29(22): 3938-3943.
[20] Fletcher, J.I., Williams, R.T., Henderson, M.J., Norris, M.D. and Haber, M. (2016) ABC Transporters as Mediators of Drug Resistance and Contributors to Cancer Cell Biology. Drug Resistance Updates, 26, 1-9. [Google Scholar] [CrossRef] [PubMed]
[21] Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S.P., et al. (2022) Epidemiology, Screening, and Prevention of Bladder Cancer. European Urology Oncology, 5, 628-639. [Google Scholar] [CrossRef] [PubMed]
[22] 李辉章, 郑荣寿, 杜灵彬, 等. 中国膀胱癌流行现状与趋势分析[J]. 中华肿瘤杂志, 2021, 43(3): 293-298.
[23] Li, S., Li, Z., Cao, Q. and Wang, W. (2020) SLC12A8 Plays a Key Role in Bladder Cancer Progression and EMT. Open Medicine, 16, 058-067. [Google Scholar] [CrossRef] [PubMed]
[24] Moresi, V., Adamo, S. and Berghella, L. (2019) The JAK/STAT Pathway in Skeletal Muscle Pathophysiology. Frontiers in Physiology, 10,Article 500. [Google Scholar] [CrossRef] [PubMed]
[25] Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H., et al. (2023) JAK/STAT Pathway: Extracellular Signals, Diseases, Immunity, and Therapeutic Regimens. Frontiers in Bioengineering and Biotechnology, 11, Article 1110765. [Google Scholar] [CrossRef] [PubMed]
[26] Feigin, M.E., Garvin, T., Bailey, P., Waddell, N., Chang, D.K., Kelley, D.R., et al. (2017) Recurrent Noncoding Regulatory Mutations in Pancreatic Ductal Adenocarcinoma. Nature Genetics, 49, 825-833. [Google Scholar] [CrossRef] [PubMed]
[27] 张晓林, 吴浩松, 汪盛. SLC12A8通过JAK/STAT途径促进膀胱癌细胞的增殖、侵袭与迁移并触发上皮间充质转化[J]. 南方医科大学学报, 2023, 43(9): 1613-1621.
[28] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[29] Wu, F., Wang, L. and Zhou, C. (2020) Lung Cancer in China: Current and Prospect. Current Opinion in Oncology, 33, 40-46. [Google Scholar] [CrossRef] [PubMed]
[30] Nie, J. and Yang, X. (2024) SLC12A8 Promotes the Migration and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells. General physiology and biophysics, 43, 445-455. [Google Scholar] [CrossRef] [PubMed]
[31] Yang, C., Yang, J.C. and Yang, P. (2020) Precision Management of Advanced Non-Small Cell Lung Cancer. Annual Review of Medicine, 71, 117-136. [Google Scholar] [CrossRef] [PubMed]
[32] Boch, T., Köhler, J., Janning, M. and Loges, S. (2022) Targeting the EGF Receptor Family in Non-Small Cell Lung Cancer—Increased Complexity and Future Perspectives. Cancer Biology & Medicine, 19, 1543-1564. [Google Scholar] [CrossRef] [PubMed]
[33] Lu, S., Zhou, J., Jian, H., Wu, L., Cheng, Y., Fan, Y., et al. (2023) Befotertinib (D-0316) versus Icotinib as First-Line Therapy for Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Randomised Phase 3 Study. The Lancet Respiratory Medicine, 11, 905-915. [Google Scholar] [CrossRef] [PubMed]
[34] Planchard, D., Jänne, P.A., Cheng, Y., Yang, J.C., Yanagitani, N., Kim, S., et al. (2023) Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 389, 1935-1948. [Google Scholar] [CrossRef] [PubMed]
[35] Yang, Y., Min, J., Yang, N., Yu, Q., Cheng, Y., Zhao, Y., et al. (2023) Envonalkib versus Crizotinib for Treatment-Naive Alk-Positive Non-Small Cell Lung Cancer: A Randomized, Multicenter, Open-Label, Phase III Trial. Signal Transduction and Targeted Therapy, 8, Article No. 301. [Google Scholar] [CrossRef] [PubMed]
[36] Drilon, A., Oxnard, G.R., Tan, D.S.W., Loong, H.H.F., Johnson, M., Gainor, J., et al. (2020) Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383, 813-824. [Google Scholar] [CrossRef] [PubMed]
[37] Barlesi, F., Mazieres, J., Merlio, J., Debieuvre, D., Mosser, J., Lena, H., et al. (2016) Routine Molecular Profiling of Patients with Advanced Non-Small-Cell Lung Cancer: Results of a 1-Year Nationwide Programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet, 387, 1415-1426. [Google Scholar] [CrossRef] [PubMed]
[38] Bonomi, P.D., Gandara, D., Hirsch, F.R., Kerr, K.M., Obasaju, C., Paz-Ares, L., et al. (2018) Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer. Annals of Oncology, 29, 1701-1709. [Google Scholar] [CrossRef] [PubMed]
[39] Huang, F., Cui, J., Wan, J., Yuan, X., Zhu, Y., Wu, X., et al. (2023) SLC12A8 Mediates TKI Resistance in EGFR-Mutant Lung Cancer via PDK1/AKT Axis. Journal of Cancer Research and Clinical Oncology, 149, 16729-16739. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, X., Wu, H. and Wang, S. (2023) [SLC12A8 Promotes Proliferation, Invasiveness, Migration and Epithelial-Mesenchymal Transition of Bladder Cancer Cells by Activating JAK/STAT Singaling]. Journal of Southern Medical University, 43, 1613-1621.
[41] Xi, Y. and Xu, P. (2021) Global Colorectal Cancer Burden in 2020 and Projections to 2040. Translational Oncology, 14, Article ID: 101174. [Google Scholar] [CrossRef] [PubMed]
[42] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[43] Sun, Z., Nie, Z., Xu, Y., Cui, Y., Ma, W. and Zhang, T. (2024) SLC12A8 Upregulation Promotes Colorectal Cancer Progression and Chemoresistance. Translational Cancer Research, 13, 3446-3464. [Google Scholar] [CrossRef] [PubMed]
[44] 聂志岩. Slc12a8转运蛋白对结肠癌化疗药物的影响研究[D]: [硕士学位论文]. 天津: 天津科技大学, 2023.
[45] Zhang, Q., Liu, Y., Chen, P., Shi, X., Liu, Y., Shi, L., et al. (2021) Solute Carrier Family 12 Member 8 (SLC12A8) Is a Potential Biomarker and Related to Tumor Immune Cell Infiltration in Bladder Cancer. Bioengineered, 12, 4946-4961. [Google Scholar] [CrossRef] [PubMed]

为你推荐